EXEL today
$70.70+$0.12 (+0.17%)close Nov 11, 2026Trend
DailyUptrend (confirmed)
4 hourStrong Bullish
1 hourSymmetric Triangle
15 minAscending Triangle
5 minBullish
Daily trend turns down below $61.67
Key levels
Resistance$73.69
Support$61.67
Support$58.59
Latest news & SEC filings
AnalystLeerink Partners keeps Market Perform on Exelixis, lifts target to $58
EarningsExel Composites hosts call on third-quarter 2026 results
All EXEL news →About Exelixis
Exelixis is an oncology-focused biopharmaceutical company that discovers and develops cancer medicines. Its main products are cabozantinib tablets and capsules, sold as CABOMETYX and COMETRIQ, used to treat kidney, liver, thyroid and neuroendocrine tumors. It also markets cobimetinib for melanoma with Genentech and esaxerenone for hypertension in Japan with Daiichi Sankyo. The company sells in the United States and through partners such as Ipsen and Takeda in other countries, and is developing additional cancer therapies including zanzalintinib.
Based on the company's 10-K filed Feb 10, 2026.
Nasdaq · Healthcare
EXELIXIS, INC. (EXEL)
What Is the Price Target for EXEL?
SEPT Low Target
$49.00
SEPT Mid Target
$58.00
SEPT High Target
$78.00
Analyst Consensus
$58.00
Is EXEL a Buy or Sell Right Now?
Thesis
- •Revenue growing 7.0% YoY with STABLE trend — consistent growth.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for EXEL.
Start Free Trial →Is EXEL Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$67.23
56
Moat Score
NARROW
6/9
Piotroski Score
20.1
Altman Z-Score
What Is Smart Money Doing with EXEL?
Insider Signal
SELLING
0 buys / 6 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| WYSZOMIERSKI JACK L | director | Sale | 3,925 | $198K | Jun 1, 2026 |
| Eckhardt Sue Gail | director | Sale | 9,812 | $492K | Jun 1, 2026 |
| PAPADOPOULOS STELIOS | director | Buy | 8,367 | - | May 27, 2026 |
| Heyman Tomas J. | director | Buy | 8,367 | - | May 27, 2026 |
| Eckhardt Sue Gail | director | Buy | 8,367 | - | May 27, 2026 |
| Smith Julie | director | Buy | 8,367 | - | May 27, 2026 |
| Freire Maria C | director | Buy | 8,367 | - | May 27, 2026 |
| Beckerle Mary C | director | Buy | 8,367 | - | May 27, 2026 |
| Oliver Bob | director | Buy | 8,367 | - | May 27, 2026 |
| WYSZOMIERSKI JACK L | director | Buy | 8,367 | - | May 27, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →EXEL Growth Story
Revenue YoY
7.0%
3yr Revenue CAGR
12.9%
EPS Growth YoY
57.95%
FCF Growth YoY
30.4%
Revenue Trend
STABLE
Dark Pool Trades for EXEL
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for EXEL, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:57:15 | $70.70 | 867,988 | $$61.4M | SELL |
| 21:00:17 | $70.70 | 2,487 | $$176K | SELL |
| 21:00:00 | $70.70 | 1,000 | $$71K | BUY |
| 20:55:49 | $70.75 | 1,100 | $$78K | MIDPOINT |
| 20:49:42 | $70.87 | 1,000 | $$71K | BUY |
5 dark pool trades shown · $$61.8M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for EXEL
PREVIEWSEPT Investing provides real-time options flow tracking for EXEL, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $80 | Jan 15 | 65 | $$150 | 1 | SWEEP |
| CALL | $55 | May 21 | 191 | $$540.0K | 300 | BLOCK |
| PUT | $55 | May 21 | 191 | $$96.0K | 300 | BLOCK |
| CALL | $48 | Nov 20 | 9 | $$685.5K | 300 | BLOCK |
| CALL | $80 | Dec 18 | 37 | $$455 | 7 | SWEEP |
5 options trades shown · 80% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About EXEL
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for EXEL. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup -- $EXEL (EXELIXIS, INC.) Price: $52.57 | Zone: $50.16 to $52.96 Conviction: HIGH | Analyst upside: +-4.9% Near resistance (86% of range) — breakout watch. Earnings: DOUBLE_BEAT. Earnings...
Join 3,500+ traders discussing EXEL in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for EXELIXIS, INC. (EXEL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →EXEL — frequently asked questions
What is EXEL stock price today?
EXELIXIS, INC. (EXEL) is at $70.70, up 0.17% (+$0.12) at the Nov 11, 2026 close.
Why is EXEL stock moving today?
Latest EXEL news — Nov 5, 2026: Leerink Partners keeps Market Perform on Exelixis, lifts target to $58 · Nov 5, 2026: Exel Composites hosts call on third-quarter 2026 results
What is the EXEL price target?
The average analyst price target for EXEL is $58.00, ranging from $49 to $78, based on 11 analysts. Latest: Leerink Partners maintains on Nov 5, 2026.
What do analysts rate EXEL?
Analyst ratings for EXEL: 0 Buy, 23 Hold, 0 Sell — consensus Hold.
Did EXEL beat earnings?
EXEL last reported on Oct 29, 2026: EPS $0.94 vs $0.89 expected — a beat of 6.0%.
What is EXEL's P/E ratio?
EXEL trades at a P/E of 21.7 vs a Healthcare average of 18.5.
Does EXEL pay a dividend?
EXEL does not currently pay a dividend.
What are EXEL support and resistance levels?
Support: $61.67, $58.59, $54.55. Resistance: $73.69.
What are insiders doing with EXEL?
Insider activity: SELLING, 0 buys and 6 sells in the last 90 days.
What is the latest news on EXEL?
Nov 5, 2026: Leerink Partners keeps Market Perform on Exelixis, lifts target to $58 · Nov 5, 2026: Exel Composites hosts call on third-quarter 2026 results